The Danish Drug Administration has published a guideline to doctors who want to prescribe cannabis. It is available here. (Danish only)

To support a further need for guidance in prescriptions and dosage, we have gathered material from Health Administrations in other countries, who have legalized cannabis for medicinal use.

Below are guidelines from Australia and Canada as well as other relevant material and links about interactions, adverse effects and research evidence.

We will update the guidelines when necessary.

Whitepapers fra (International Cannabis and Cannabinoids Institute, Czech Rep.)

Introduction to the Endocannabinoid System (2019) by Ethan Russo, MD, ICCI Research & Development Director

Pharmacodynamics of Cannabinoids (2019) by Prof. MUDr. Alexandra Šulcová, CSc., FCMA, FECNP, FCINP

Cannabidiol (CBD) and Hemp: Novel Food Status in the EU. (2018) by Martin Másílko, Tomáš Sadílek, Teresa Martin and Erik Jurado

All papers are available here:

Practical considerations in medical cannabis administration and dosing

Artikle from European Journal of Internal Medicine 

Journal of Internal Medicine

Guidelines from Australia


Guidelines from Canada     

Guidelines from Queensland, Australia

Adverse effects and interactions

Abstract: Important drug interactions exist between cannabidiol oil and commonly prescribed drugs in rheumatology practice

Cannabinoid Drug Interactions (klik på billedet)



Evidence collection

Lectures from CannX 2018

  • Nadav Eyal, speaking on “Eybna Technologies on Bio-control Program in Cannabis” here.
  • Adi Aran speaking on cannabis for medicinal use for children with autism here.
  • Moving lecture on Canadian veterans suffering from PTSD, who have been treated with cannabis here.
  • David Meiri speaks about “The Science Behind the Entourage Effect” her.
  • Prof. Donald Abrams CannX 2018 on cancer studies here.